ARCH Venture Partners — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Vividion Therapeuticsvividion.cominApr 2019acquired by Bayer
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)
Board seatKristina BurowRichard Heyman· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.